Micro-RNA profiling in kidney and bladder cancers.

By F. Gottardo, C. G. Liu, M. Ferracin, George A. Calin, M. Fassan, P. Bassi, C. Sevignani, D. Byrne, M. Negrini, F. Pagano and 3 more. Urologic oncology, 2007

645 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/d5ecfe48a88fb1865ca1ee148362ceb23c63ee7b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. M. Ferracin
2. M. Negrini
3. Carlo Maria Croce
4. George A. Calin

In Molecular Biology

1. E. Song
2. M. Ferracin
3. M. Negrini
4. Carlo Maria Croce
5. George A. Calin

Citations in the corpus

• MicroRNAs and complex diseases: from experimental results to computational models (2019, neutral): “Owing to the refractory nature of kidney cancer, patients usually suffer from high rates of metastatic recurrences [ 30% of localized renal cell carcinoma (RCC) cases] and death (5-year survival rate of 60– 70%) [139, 140].”
• MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma (2008, background): “, 2005), urinary bladder cancer (Gottardo et al., 2007), papillary tumors of the thyroid (He et al.”
• Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells (2011, background): “miR-223 has been implicated in the progression of renal [26] and hepatocellular cancers [27].”